Subscribe to The Free Market Chronicle and join the 2,680 subscribers getting it for FREE!

[widget id=”text-23″]

Micron’s Massive Breakout, Plus Skyworks, Lam, Biogen, Alnylam & More

The stock market was mixed on Monday, with the S&P 500 finishing the day down slightly. Technology and Biotechnology continue to be the best performing sectors in the market, with the Nasdaq Biotech IBB rising by 40 bps, and the Technology ETF XLK rising by 45 bps. The semiconductor ETF SOXX was the best performing group up another over 1 percent.

[widget id=”text-19″]

[widget id=”text-16″]

Micron

Micron’s stock was the most prominent winner up by nearly 9 percent, with the stock eclipsing the $58 technical level we had been targeting for some time. The move higher came after Nomura raised its price target on the stock to amazing $100, nearly doubling its previous target of $55. Meanwhile, Evercore upgraded the stock to $80 from $60.

If you are a Micron bull, then the good news, is the next resistance level comes somewhere around $68.

Option volume was also very bullish today as well, with nearly 41,000 call contracts trading at the $55 strike price, an implies a breakeven price of nearly $62. Meanwhile, 30,000 calls contracts traded at the $60, and implies a breakeven price of nearly $64.

[widget id=”text-22″]

Skyworks

Skyworks has quietly worked its way back to nearly an all-time high. So much for the Apple supercycle issues. That is likely because Skyworks continues to diversify its customers away from Apple and continues to drive earnings and revenue growth.

[widget id=”text-21″]

Lam

Lam Research broke out, rising above its previous high, on surging volume. Could shares climb all the way to $250? It doesn’t seem outside of the realm of possibility.

Biogen

Biogen shares better find a bounce or the final nail may be put in the coffin of this stock. The stock sits on it technical support level around $280, and should this break below $275; it is likely headed another 11 percent lower, towards $250.

Alnylam

Shares of Alnylam broke out today, crossing above $139.50 its previous all-time high.

If the old guard biotechs aren’t going to lead the group higher, other companies are going to have to pick up the slack. Today it was Alnylam, Alkermes, and Seattle Genetics turn.

[widget id=”wordads_sidebar_widget-41″]

Alkermes

Alkermes has been floating above and below the $60 mark for some time, and it will be interesting to see if the stock can finally pull away to the upside. There is only a little bit of open interest at the May 2018 calls at the $60 strike price, with 1,700 contracts open. The calls cost about $5.00 bucks It is small bet, with a notional value of approximately $1.0 million, but the options are expensive with an implied volatility of nearly 48 percent. The stock would have to rise to about $65 to break even.

Seattle Genetics

Seattle Genetics is either close to a massive breakout or colossal breakdown. It looks a like a symmetrical triangle in the chart, and that would suggest a continuation of the prior uptrend. A Rise above $60 could bring the breakout.

[widget id=”wordads_sidebar_widget-41″]

Charter

Charter, the cable company, is a new one for us to explore and was one of the better consumer discretionary names today. The chart has a strong set-up. We will have to keep an eye.

That’s It.

[widget id=”wordads_sidebar_widget-41″]

[widget id=”text-22″]

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Micron Jumps, Nvidia’s Breakout

Market Surges Breakouts All Over

Roku Borrow Rate Surge, Biotech Fakeout?

Tech And Biotech Look Weak, Plus Subscriber Mailbag

What The Heck Happened

Free Articles Written By Mike:

Nvidia’s Breakout Seen Fueling 14% Stock Gain

Why Overvalued Gilead May Fall 10%

3 Chip Stocks Poised to Rise as Much as 26%

Facebook Seen Rising 20% Defying Skeptics

Roku Shares Could Fall 50% Further

Why Micron’s Stock Bulls May Be Wrong

Why Bank Stocks Are Ready for a Short-Term Pullback

Join our 2,680 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo credit via Flickr

Michael Kramer and the clients of Mott Capital own shares of SWKS, ALKS

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

Tags: #sp500 #biotech #technology #micron #lam #skyworks #biogen #alnylam #alkermes #charter